Lung Cancer Symptom Assessment and Management Intervention
The purpose of this study is to develop and test the usability of a computerized symptom assessment and management intervention system in a laboratory setting (phase I) and its feasibility in a clinical setting in a group randomized trial (phase II).
Checked against the public recordLast updated Oct 21, 2016 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Supportive Care
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Dana-Farber Cancer Institute
- Interventions being studied
- Behavioral: SAMI
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * HCPs: attending physician, thoracic medical oncologist, expected to work in the setting for at least 2 years. * Patients: 21 years of age or older; diagnosis of Stage IIIA, IIIB, IV non-small cell lung cancer OR limited or extensive stage small cell lung cancer; receiving care in the out-patient setting; receiving treatment with chemotherapy +/- additional therapies; English speaking. Exclusion Criteria: * Patients: Any patient who needs emergent care, routine visits scheduled less than once a month
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Dana-Farber Cancer InstituteBoston, Massachusetts
- Boston Medical CenterBoston, Massachusetts
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 21, 2016. Always confirm current availability with the study team.